RenovoRx, Inc. RNXT
RenovoRx, Inc. (Nasdaq: RNXT) is an oncology drug developer. Its lead program, Intra-arterial gemcitabine (IAG) delivered via RenovoCath, is in Phase 3 for Locally advanced pancreatic cancer (LAPC). Its next catalyst on record is IAG via RenovoCath for LAPC (TIGeR-PaC trial): Initial top-line data from Phase III TIGeR-PaC trial (H2 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: IAG via RenovoCath for LAPC (TIGeR-PaC trial) — Initial top-line data from Phase III TIGeR-PaC trial (H2 2027). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| IAG (intra-arterial gemcitabine) via RenovoCath for LAPC | Locally advanced pancreatic cancer | small molecule | Phase 3 |
| RenovoCath for borderline resectable pancreatic cancer | Borderline resectable pancreatic cancer | device-combination | Phase 2 |
| RenovoCath for metastatic pancreatic cancer | Metastatic pancreatic cancer | device-combination | Phase 2 |
| RenovoCath for cholangiocarcinoma | Cholangiocarcinoma (bile duct cancer) | device-combination | Phase 2 |
| PRISM-TAMP (gemcitabine via TAMP platform) | Neoadjuvant setting for planned surgical resection | small molecule | Phase 1 |
Recent results and decisions
- Aug 12, 2026completed enrollment TIGeR-PaC Phase 3 reached full enrollment; investigators notified Aug 7, 2026 that enrollment is closing; 78 of 86 required events observed.
Recently, RenovoRx announced that it achieved full enrollment in its Phase III TIGeR-PaC trial evaluating intra-arterial delivery of intra-arterial gemcitabine (IAG) via the RenovoCath device for the treatment of LAPC.
Filing - completed enrollment RenovoRx completed enrollment in Phase III TIGeR-PaC trial in August 2026.
RenovoRx completed enrollment in the Phase III TIGeR-PaC clinical trial in August 2026, and anticipates the initial topline data in the second half of 2027.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Astrazeneca PLC AZN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Guardant Health, Inc. GH
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.